28,580 Alzheimer's and dementia studies in plain English, each scored out of 100.
The findings indicate for the first time in humans that PTSD is associated with selective volume loss of the CA3/dentate gyrus subfields, consistent with animal studies, implying that chronic stress suppresses neurogenesis and dendritic branching in these structures. 4 key findings →
Design: case-control study Participants: 17 Evidence: moderate
Full summary, score breakdown and related studies → Original source
The APOE epsilon4 allele acts as a potent risk factor for AD by accelerating onset. 1 key finding →
Design: longitudinal study Participants: 3,308 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Although statin use might be less frequent in those with prevalent dementia, we found no association between statin use and subsequent onset of dementia or AD. 3 key findings →
Design: cross-sectional Participants: 4,895 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The p-tau proteins in CSF come closest to fulfilling the criteria of a biological marker of AD. 2 key findings →
Design: cross-sectional Participants: 206 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Furthermore, the CSF biomarker analyses provide a first insight into the potentially predominant pathogenetic mechanism(s) underlying the association between AD risk and PICALM. 1 key finding →
Design: case-control study Participants: 4,254 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Depressive symptoms appeared to be early manifestations, rather than predictors, of Alzheimer disease in this community sample. 3 key findings →
Participants: 1,366 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Specific alleles of the DISC1 and TRAX genes on 1q42 appear to contribute to genetic risk for schizophrenia through disruptive effects on the structure and function of the prefrontal cortex, medial temporal lobe, and other brain regions. 2 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source
Atrophy of the hippocampus and amygdala on MRI in cognitively intact elderly people predicts dementia during a 6-year follow-up. 5 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Early detection of prodromal Alzheimer disease (AD) is important because new disease-modifying therapies are most likely to be effective when initiated during the early stages of disease. 4 key findings →
Participants: 137 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
In the sertraline-treated group 9 patients (38%) were full responders and 11 (46%) were partial responders compared with 3 (20%) and 4 (15%), respectively, in the placebo-treated group (P =.007). 3 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Late-life depression is characterized by slowed information processing, which affects all realms of cognition. 2 key findings →
Design: cross-sectional Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Misidentification, wandering or agitation, and physical aggression increased during follow-up. 5 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source
Patients with AD and patients with FTD show different disturbances in their rhythms of activity and temperature compared with each other and with normal elderly patients. 3 key findings →
Participants: 23 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Depressive symptoms are cross-sectionally associated with cognitive impairment but not subsequent cognitive decline. 5 key findings →
Participants: 1,265 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
In 1999, 17.7% (95% confidence interval [CI], 17.2-18.1) of patients with dementia were using atypical or conventional antipsychotics. 3 key findings →
Participants: 254 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
In later-myelinating regions, the severity and rate of myelin breakdown in healthy older individuals are associated with APOE status and support the hypothesis that this process may contribute to age at onset of AD. 5 key findings →
Design: cross-sectional Participants: 104 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Adults with DS have a significantly increased brain concentration of myo-inositol, and this is associated with reduced cognitive ability. 5 key findings →
Design: case-control study Participants: 38 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Patients with chronic schizophrenia displayed bilateral hippocampal volume reduction. 4 key findings →
Design: cross-sectional Participants: 89 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Executive dysfunction was found to be associated with relapse and recurrence of geriatric major depression and with residual depressive symptoms. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Physostigmine demonstrated a statistically significant benefit compared with placebo on a clinical global rating of change and an objective test of cognitive function. 3 key findings →
Participants: 850 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Elevated beta-secretase (beta-site amyloid precursor protein-cleaving enzyme 1 [BACE1]) activity has been found in the brains of patients with sporadic Alzheimer disease (AD) compared with controls. 4 key findings →
Participants: 59 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
We sought to determine whether neuropsychological impairment in schizophrenia is related to current age, age at onset, or duration of illness, and whether the pattern of such impairment can be distinguished from that caused by progressive dementias of Alzheimer's type. 4 key findings →
Participants: 38 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Cognitive impairment and late-life depression are associated with increased risk for subsequent dementia; however, investigations of these phenomena appear to be proceeding along separate tracks. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
In these high-risk patients, antidepressant drug treatment does not seem to be related to suicide attempts and death in adults but might be related in children and adolescents. 4 key findings →
Design: case-control study Evidence: moderate
Full summary, score breakdown and related studies → Original source
A substantial proportion of persons with AD who were thought incapable of consenting to lower-risk or higher-risk studies have preserved capacity for appointing a research proxy. 2 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 28,580 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,580 records, built mostly from automated pulls of Europe PMC (62.2% of the library) and OpenAlex (17.8%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.6% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →